Regencell Bioscience Lim... (RGC)
NASDAQ: RGC
· Real-Time Price · USD
17.10
0.95 (5.88%)
At close: Oct 03, 2025, 3:59 PM
16.99
-0.64%
After-hours: Oct 03, 2025, 07:45 PM EDT
Regencell Bioscience Cash Flow Statement
Financials in USD. Fiscal
year is
July - June.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 |
Net Income | -4.09K | -4.19K | -4.3K | -4.51K | -4.71K | -5.29K | -5.87K | -6.48K | -7.08K | -7.26K | -7.45K | -6.03K | -4.6K | -2.98K | -1.35K | -1.1K | -848.2 | -830.29 |
Depreciation & Amortization | n/a | n/a | n/a | 769.69K | 769.69K | 769.69K | 769.69K | 415.6M | 415.6M | 415.6M | 415.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 550.00 | 510.00 | 470.00 | 335.00 | 200.00 | 550.00 | 900.00 | 1.48K | 2.06K | 2.41K | 2.76K | -7M | -7M | -7M | -7M | n/a | n/a | n/a |
Other Working Capital | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 31.6M | 31.6M | 31.6M | 31.6M | 303.12 | 303.12 | 303.12 | 303.12 | n/a | n/a | n/a |
Other Non-Cash Items | 3.54K | 3.68K | 3.83K | 4.16K | 4.48K | 4.71K | 4.94K | 4.98K | 5.02K | 4.85K | 4.68K | 3.34K | 2.49K | 1.5K | 506.45 | 506.45 | n/a | n/a |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3.9M | -3.9M | -3.9M | -3.9M | -3.9M | -3.9M | -3.9M | -3.9M | n/a | n/a | n/a |
Change in Working Capital | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 147.7M | 147.7M | 147.7M | 147.7M | 303.12 | 303.12 | 303.12 | 303.12 | n/a | n/a | n/a |
Operating Cash Flow | n/a | n/a | n/a | 1.54M | 1.54M | 1.54M | 1.54M | -5.43B | -5.43B | -5.43B | -5.43B | -196.77 | -196.77 | -383.66 | -570.54 | -578.68 | -783.6 | -755.09 |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -575.18M | -575.18M | -575.18M | -575.18M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -9.63B | -9.63B | -9.63B | -9.63B | 160M | 160M | 160M | 160M | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -10.42B | -10.42B | -10.42B | -10.42B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -103.6M | -103.6M | -103.6M | -103.6M | -103.6M | -103.6M | -103.6M | -103.6M | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 22.48B | 22.48B | 22.48B | 22.48B | 103.6M | 103.6M | 103.6M | 103.6M | 308.01 | 308.01 | 649.77 |
Financial Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 22.38B | 22.38B | 22.38B | 22.38B | n/a | n/a | 154.01 | 308.01 | 308.01 | 308.01 | 649.77 |
Net Cash Flow | n/a | n/a | n/a | 1.54M | 1.54M | 1.54M | 1.54M | 6.19B | 6.19B | 6.19B | 6.19B | -228.74M | -228.74M | -228.74M | -228.74M | -239.92 | -479.84 | -168.08 |
Free Cash Flow | n/a | n/a | n/a | 1.54M | 1.54M | 1.54M | 1.54M | -6B | -6B | -6B | -6B | -189.14 | -189.14 | -383.66 | -578.17 | -627.23 | -865.43 | -854.92 |